The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes

Bibliography

• BUSE J, GINSBERG H, BAKRIS G et al.: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American heart association and the American diabetes association. Diabetes Care (2007) 30(1):162-172.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM, LEHTO S, RONNEMAA T, PYORALA K, LAAKSO M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. (1998) 339(4):229-234.
   PubMed Web of Science ®Google Scholar
• ZELLWEGER M: Prognostic significance of silent coronary artery disease in type 2 diabetes. Herz (2006) 31(3):240-245.
   PubMedGoogle Scholar
• PRADHAN AD, RIDKER PM: Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur. Heart J. (2002) 23(11):831-834.
   PubMed Web of Science ®Google Scholar
• HOTAMISLIGIL GS: Inflammatory pathways and insulin action. Int. J. Obes. Relat. Metab. Disord. (2003) 27(Suppl. 3):S53-S55.
   PubMed Web of Science ®Google Scholar
• HOTAMISLIGIL GS, SHARGILL NS, SPIEGELMAN BM: Adipose expression of TNF-α: direct role in obesity-linked insulin resistance. Science (1993) 259(5091):87-91.
   PubMed Web of Science ®Google Scholar
• DIAMANT M, LAMB HJ, VAN DE REE MA et al.: The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J. Clin. Endocrinol. Metab. (2005) 90(3):1495-1501.
   PubMed Web of Science ®Google Scholar
• HASLAM DW, JAMES WP: Obesity. Lancet (2005) 366(9492):1197-1209.
   PubMed Web of Science ®Google Scholar
• DESPRES JP: Health consequences of visceral obesity. Ann. Med. (2001) 33(8):534-541.
   PubMed Web of Science ®Google Scholar
• VAGUE J: La différenciation sexuelle, facteur déterminant des formes de l'obésité. Presse Med. (1947) 30:339-340.
   Google Scholar
• POULIOT MC, DESPRES JP, LEMIEUX S et al.: Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol. (1994) 73(7):460-468.
   PubMed Web of Science ®Google Scholar
• KERSHAW EE, FLIER JS: Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. (2004) 89(6):2548-2556.
   PubMed Web of Science ®Google Scholar
• PARASKEVAS KI, LIAPIS CD, MIKHAILIDIS DP: Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr. Drug Targets (2006) 7(6):761-771.
   PubMed Web of Science ®Google Scholar
• WALLACE AM, MCMAHON AD, PACKARD CJ et al.: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation (2001) 104(25):3052-3056.
   PubMed Web of Science ®Google Scholar
• COUILLARD C, LAMARCHE B, MAURIEGE P et al.: Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Diabetes Care (1998) 21(5):782-786.
   PubMed Web of Science ®Google Scholar
• SCHROETER MR, SCHNEIDERMAN J, SCHUMANN B et al.: Expression of the leptin receptor in different types of vascular lesions. Histochem. Cell Biol. (2007).
   PubMedGoogle Scholar
• CHAO HH, HONG HJ, LIU JC et al.: Leptin stimulates endothelin-1 expression via extracellular signal-regulated kinase by epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. Eur. J. Pharmacol. (2007).
   PubMedGoogle Scholar
• JAGROOP IA, DASKALOPOULOU SS, MIKHAILIDIS DP: Endothelin-1 and human platelets. Curr. Vasc. Pharmacol. (2005) 3(4):393-399.
   PubMedGoogle Scholar
• CHANDRAN M, PHILLIPS SA, CIARALDI T, HENRY RR: Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 26(8):2442-2450.
   PubMed Web of Science ®Google Scholar
• OUCHI N, KIHARA S, ARITA Y et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation (1999) 100(25):2473-2476.
   PubMed Web of Science ®Google Scholar
• KOHLER HP, GRANT PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. (2000) 342(24):1792-1801.
   PubMed Web of Science ®Google Scholar
• FESTA A, D'AGOSTINO R Jr, TRACY RP, HAFFNER SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 51(4):1131-1137.
   PubMed Web of Science ®Google Scholar
• YUDKIN J, KUMARI M, HUMPHRIES S, MOHAMED-ALI V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis (2000) 148(2):209-214.
   PubMed Web of Science ®Google Scholar
• RUAN H, MILES PD, LADD CM et al.: Profiling gene transcription in vivo reveals adipose tissue as an immediate target of TNF-α: implications for insulin resistance. Diabetes (2002) 51(11):3176-3188.
   PubMed Web of Science ®Google Scholar
• ECKEL RH, GRUNDY SM, ZIMMET PZ: The metabolic syndrome. Lancet (2005) 365(9468):1415-1428.
   PubMed Web of Science ®Google Scholar
• YUDKIN JS: Adipose tissue, insulin action and vascular disease: inflammatory signals. Int. J. Obes. Relat. Metab. Disord. (2003) 27(Suppl. 3):S25-S28.
   PubMed Web of Science ®Google Scholar
• KOENIG W, SUND M, FROHLICH M et al.: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg Cohort study, 1984 to 1992. Circulation (1999) 99(2):237-242.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, ROSE L, BURING JE, COOK NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. (2002) 347(20):1557-1565.
   PubMed Web of Science ®Google Scholar
• SAKKINEN P, ABBOTT R, CURB J et al.: C-reactive protein and myocardial infarction. J. Clin. Epidemiol. (2002):445-451.
   PubMedGoogle Scholar
• FORD ES, GILES WH: Serum C-reactive protein and self-reported stroke: findings from the third National health and nutrition examination survey. Arterioscler. Thromb. Vasc. Biol. (2000) 20(4):1052-1056.
   PubMed Web of Science ®Google Scholar
• RUTTER MK, MEIGS JB, SULLIVAN LM, D'AGOSTINO RB Sr, WILSON PWF: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation (2004) 110(4):380-385.
   PubMed Web of Science ®Google Scholar
• KAHN SE, ZINMAN B, HAFFNER SM et al.: Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes (2006) 55(8):2357-2364.
   PubMedGoogle Scholar
• MALIK S, WONG ND, FRANKLIN S et al.: Cardiovascular disease in US patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care (2005) 28(3):690-693.
   PubMed Web of Science ®Google Scholar
• PU LJ, LU L, XU XW et al.: Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc. Diabetol. (2006) 5:27.
   PubMedGoogle Scholar
• LINNEMANN B, VOIGT W, NOBEL W, HU J: C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp. Clin. Endocrinol. Diabetes (2006) 114(3):127-134.
   PubMed Web of Science ®Google Scholar
• SMITH SC Jr, ANDERSON JL, CANNON RO III et al.: CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the clinical practice discussion group. Circulation (2004) 110(25):E550-E553.
   PubMed Web of Science ®Google Scholar
• PEARSON TA, MENSAH GA, ALEXANDER RW et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation (2003) 107(3):499-511.
   PubMed Web of Science ®Google Scholar
• PASCERI V, WILLERSON JT, YEH ETH: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation (2000) 102(18):2165-2168.
   PubMed Web of Science ®Google Scholar
• JIALAL I, DEVARAJ S, VENUGOPAL SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension (2004) 44(1):6-11.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN D: Beneficial health effects of modest weight loss. Int. J. Obes. Relat. Metab. Disord. (1992) 16(6):397-415.
   PubMed Web of Science ®Google Scholar
• ESMAILLZADEH A, KIMIAGAR M, MEHRABI Y et al.: Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. Am. J. Clin. Nutr. (2006) 84(6):1489-1497.
   PubMed Web of Science ®Google Scholar
• JAE S, FERNHALL B, HEFFERNAN K et al.: Effects of lifestyle modifications on C-reactive protein: contribution of weight loss and improved aerobic capacity. Metabolism (2006) 55(6):825-831.
   PubMedGoogle Scholar
• SELVIN E, PAYNTER N, ERLINGER T: The effect of weight loss on C-reactive protein: a systematic review. Arch. Intern. Med. (2007) 167(1):31-39.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS JA, MILIONIS HJ, PRESS M, MIKHAILIDIS DP: Treating dyslipidaemia in non-insulin-dependent diabetes mellitus – a special reference to statins. J. Diabetes Complications (2001) 15(4):211-226.
   PubMed Web of Science ®Google Scholar
• VIJAN S, HAYWARD RA: Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American college of physicians. Ann. Intern. Med. (2004) 140(8):650-658.
   PubMed Web of Science ®Google Scholar
• ATHYROS VG, KAKAFIKA AI, PAPAGEORGIOU AA et al.: Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids (2007).
   PubMedGoogle Scholar
• ALBERT MA, DANIELSON E, RIFAI N, RIDKER PM; FOR THE PRINCE INVESTIGATORS: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 286(1):64-70.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, CANNON CP, MORROW D et al.: C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. (2005) 352(1):20-28.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. (2005) 352(1):29-38.
   PubMed Web of Science ®Google Scholar
• KINLAY S: Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J. Am. Coll. Cardiol. (2007) 49(20):2003-2009.
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation (2000) 102(1):21-27.
   PubMedGoogle Scholar
• KEECH A, SIMES R, BARTER P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 366(9500):1849-1861.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of Veterans affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. (2002) 162(22):2597-2604.
   PubMed Web of Science ®Google Scholar
• STAELS B, KOENIG W, HABIB A et al.: Activation of human aortic smooth-muscle cells is inhibited by PPAR[α] but not by PPAR[γ] activators. (1998) 393(6687):790-793.
   Google Scholar
• TSIMIHODIMOS V, KOSTOULA A, KAKAFIKA A et al.: Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J. Cardiovasc. Pharmacol. Ther. (2004) 9:27-33.
   PubMed Web of Science ®Google Scholar
• RIZOS E, KOSTOULA A, ELISAF M, MIKHAILIDIS DP: Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology (2002) 53(3):273-277.
   PubMed Web of Science ®Google Scholar
• CANNER P, FURBERG C, MCGOVERN M: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the coronary drug project). Am. J. Cardiol. (2006) 97(4):477-479.
   PubMed Web of Science ®Google Scholar
• ELAM MB, HUNNINGHAKE DB, DAVIS KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial. JAMA (2000) 284(10):1263-1270.
   PubMed Web of Science ®Google Scholar
• PEARSON TA, DENKE MA, MCBRIDE PE et al.: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. (2005) 80(5):587-595.
   PubMed Web of Science ®Google Scholar
• MIKHAILIDIS DP, SIBBRING GC, BALLANTYNE CM, DAVIES GM, CATAPANO AL: Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. Opin. (2007) 23(8):2009-2026.
   PubMed Web of Science ®Google Scholar
• GAZI IF, DASKALOPOULOU SS, NAIR DR, MIKHAILIDIS DP: Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr. Med. Res. Opin. (2007).
   Google Scholar
• KALOGIROU M, TSIMIHODIMOS V, GAZI I et al.: Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr. Med. Res. Opin. (2007) 23(5):1169-1176.
   PubMed Web of Science ®Google Scholar
• NATHAN DM, CLEARY PA, BACKLUND JY et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. (2005) 353(25):2643-2653.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352(9131):837-853.
   PubMed Web of Science ®Google Scholar
• UKPDS GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (1998) 352(9131):854-865.
   PubMed Web of Science ®Google Scholar
• SATOH N, OGAWA Y, USUI T et al.: Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care (2003) 26(9):2493-2499.
   PubMed Web of Science ®Google Scholar
• AGARWAL R: Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am. J. Physiol. Renal Physiol. (2006) 290(3):F600-F605.
   PubMed Web of Science ®Google Scholar
• MATTOO V, ECKLAND D, WIDEL M et al.: Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin. Ther. (2005) 27(5):554-567.
   PubMed Web of Science ®Google Scholar
• REYNOLDS L, KINGSLEY F, KAROUNOS D, TANNOCK L: Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res. Clin. Pract. (2007) 77(2):180-187.
   PubMedGoogle Scholar
• YU D, MURDOCH S, PARIKH S et al.: Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diab. Vasc. Dis. Res. (2006) 3(3):189-196.
   PubMedGoogle Scholar
• HOME PD, POCOCK SJ, BECK-NIELSEN H et al.: Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N. Engl. J. Med. (2007):NEJMoa073394.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, WOLSKI K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356(24):2457-2471.
   PubMed Web of Science ®Google Scholar
• LINDBERG M, ASTRUP A: The role of glitazones in management of type 2 diabetes. A DREAM or a nightmare? Obes. Rev. (2007) 8(5):381-384.
   PubMedGoogle Scholar
• GERRITS CM, BHATTACHARYA M, MANTHENA S et al.: A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol. Drug Saf. (2007).
   PubMedGoogle Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ (1998) 317(7160):703-713.
   PubMedGoogle Scholar
• PERSSON F, ROSSING P, HOVIND P et al.: Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes (2006) 55(12):3550-3555.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, FONSECA V, KATHOLI RE et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 292(18):2227-2236.
   PubMed Web of Science ®Google Scholar
• KARAGIANNIS A, MIKHAILIDIS DP, TZIOMALOS K, KAKAFIKA AI, ATHYROS VG: Has the time come for a new definition of microalbuminuria? Expert Opin. Pharmacother. (2007).
   Google Scholar
• FINER N: Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur. Heart J. (2005) 7(Suppl. 7):L32-L38.
   Google Scholar
• LI Z, MAGLIONE M, TU W et al.: Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med. (2005) 142(7):532-546.
   PubMed Web of Science ®Google Scholar
• PADWAL R, MAJUMDAR S: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet (2007) 369:71-77.
   PubMedGoogle Scholar
• JAMES WP, ASTRUP A, FINER N et al.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet (2000) 356(9248):2119-2125.
   PubMed Web of Science ®Google Scholar
• FILIPPATOS TD, KIORTSIS DN, LIBEROPOULOS EN et al.: Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr. Med. Res. Opin. (2005) 21(12):1997-2006.
   PubMed Web of Science ®Google Scholar
• PI-SUNYER FX, ARONNE LJ, HESHMATI HM, DEVIN J, ROSENSTOCK J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA (2006) 295(7):761-775.
   PubMed Web of Science ®Google Scholar
• VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365(9468):1389-1397.
   PubMed Web of Science ®Google Scholar
• DESPRES JP, GOLAY A, SJOSTROM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353(20):2121-2134.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ, FINER N, HOLLANDER P, JENSEN MD, VAN GAAL LF: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 368(9548):1660-1672.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI AS: Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int. J. Clin. Pract. (2006) 60(12):1697-1706.
   PubMedGoogle Scholar
• VAN GAAL L, SCHEEN A, DESPRES JP et al.: Effect of rimonabant on systolic and diastolic blood pressure in overweight/obese patients with/without co-morbidities. European Society of Hypertension Annual Meeting. Madrid, Spain (2006).
   Google Scholar
• IRANMANESH A, ROSENSTOCK J, HOLLANDER P; ON BEHALF OF THE SERENADE STUDY GROUP: SERENADE: rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naïve patients with type 2 diabetes. The International Diabetes Federation 19th World Diabetes Congress. Cape Town, South Africa (3 – 7 December 2006).
   Google Scholar
• KAKAFIKA AI, MIKHAILIDIS DP, KARAGIANNIS A, ATHYROS VG: The role of endocannabinoid system bockade in the treatment of the metabolic syndrome. J. Clin. Pharmacol. (2007) 47:642-652.
   PubMed Web of Science ®Google Scholar
• JBS2: JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 91(Suppl. 5):V1-V52.
   Google Scholar
• GAEDE P, VEDEL P, LARSEN N et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. (2003) 348(5):383-393.
   PubMed Web of Science ®Google Scholar
• LIBEROPOULOS EN, TSOULI S, MIKHAILIDIS DP, ELISAF MS: Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr. Drug Targets (2006) 7(2):211-228.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ: DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease. Revue medicale de Liege (2006) 61(10):728-732.
   PubMedGoogle Scholar
• AKSNES TA, KJELDSEN SE, ROSTRUP M et al.: Impact of new-onset diabetes mellitus on cardiac outcomes in the valsartan antihypertensive long-term use evaluation (VALUE) trial population. Hypertension (2007) 50(3):467-473.
   PubMed Web of Science ®Google Scholar
• TORGERSON JS, HAUPTMAN J, BOLDRIN MN, SJOSTROM L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 27(1):155-161.
   PubMed Web of Science ®Google Scholar
• Shape of the Nations. World Heart Federation (2005).
   Google Scholar
• WIERZBICKI AS, GANOTAKIS ES, MIKHAILIDIS DP: Shape of the Nations survey and attitudes to cardiometabolic risk. Curr. Med. Res. Opin. (2007) 23(1):25-28.
   PubMed Web of Science ®Google Scholar